Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: HEPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hepion Pharmaceuticals, Inc. (HEPA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, registration statements and other documents filed with the U.S. Securities and Exchange Commission. Hepion describes itself as a clinical stage biopharmaceutical company that had been developing rencofilstat for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC) and other chronic liver diseases, and that is transitioning toward the development and commercialization of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and HCC.
Through its SEC filings, Hepion reports material events and strategic changes such as executive departures, board decisions and restructuring plans. For example, a current report on Form 8-K details the resignation of a chief financial officer and director. Other filings referenced in company news include registration statements on Form S-1 for public offerings of common stock and warrants, and a registration statement on Form F-4 related to a proposed merger with Pharma Two B Ltd. that was later terminated by mutual agreement.
Filings also document capital structure and listing developments, including the mechanics and rationale of a reverse stock split intended to address Nasdaq’s minimum bid price requirement, as well as disclosures surrounding a subsequent delisting notification from Nasdaq. Investors can use these documents to understand how Hepion has managed its equity, responded to listing standards, and transitioned its common stock to trading on the OTCQB Venture Market.
For those analyzing Hepion’s pipeline and asset monetization, SEC filings and incorporated disclosures describe the wind-down and closure of the ASCEND-NASH Phase 2b trial and the sale of rencofilstat-related patents, knowhow, clinical trial data and drug product, along with the grant of a contingent value right to stockholders. Stock Titan’s platform surfaces these filings with AI-powered summaries that highlight key terms, risk factors and transaction details, helping readers navigate complex documents such as registration statements and current reports without having to parse every page manually.
In addition, users can review historical filings related to Hepion’s strategic restructuring plan, its exploration of strategic and financing alternatives, and its shift toward licensed diagnostic tests. Real-time updates from EDGAR combined with AI-generated insights make this page a focused resource for understanding how Hepion’s regulatory disclosures reflect its move from liver drug development to precision diagnostics and its evolving public company status.
Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as Chief Executive Officer effective January 8, 2026, under a new employment agreement. She will receive an annual base salary of $350,000 and is eligible for an annual discretionary cash bonus targeted at 35% of base salary, based on goals set by the Board. Of the base salary, $50,000 is deferred and paid in cash only upon a qualifying equity financing of at least $3,000,000, certain termination events, or a change of control.
If a change of control occurs with an enterprise value of at least $5,000,000, Dr. Lbiati earns a bonus equal to 3.0% of that value. The agreement provides severance of six months of base compensation, benefits, and a pro-rated bonus if she is terminated without cause or resigns for good reason, along with full vesting of time-based equity awards. Additional protections apply in connection with death, disability, and specified change-of-control related terminations, including accelerated vesting and extended exercise periods for equity awards.
Hepion Pharmaceuticals (HEPA) filed its Q3 2025 10‑Q, showing a continued business pivot from liver drug development to medical diagnostics. The company reported a Q3 net loss of $472,506 and a nine‑month net loss of $7,620,965. Operating expenses fell sharply as research and development dropped to zero for the quarter, while general and administrative expense was $527,902.
Cash was $2,321,078 at September 30, 2025, with total liabilities of $415,808 and stockholders’ equity of $3,324,432. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. Shares outstanding were 11,620,317 as of November 12, 2025.
Hepion in‑licensed diagnostic tests from New Day Diagnostics on May 9, 2025, paying $525,000 cash and $270,629 in stock, with up to $17.15 million in potential milestones; it recorded a $402,746 impairment. On May 26, 2025, it sold all rencofilstat assets to Panetta Partners for a nominal amount, with CVRs tied to future FDA approval and sales milestones. Earlier, the company raised approximately $9.0 million (January 23, 2025), repaid $2.9 million notes, effected a 1‑for‑50 reverse split, and transitioned trading to OTCQB after Nasdaq delisting.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) filed a Form 8-K to disclose the resignation of Chief Financial Officer and director John Brancaccio. His departure, attributed to personal reasons, is effective June 30, 2025. The filing, made pursuant to Item 5.02, notes that Kaouthar Lbiati signs as Interim CFO. No additional management changes, compensation details, or financial data were provided.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
